elenbecestat + rifampin

Elenbecestat + rifampin is a combination of two drugs: elenbecestat (E2609), an oral small molecule inhibitor of Beta-secretase 1 (BACE1), and rifampin, an antibiotic commonly used to treat tuberculosis and other bacterial infections. Elenbecestat, developed by Eisai and Biogen, acts by inhibiting BACE1, a key enzyme in the production of amyloid-beta (Aβ) peptides, and is being investigated for the treatment of Alzheimer's disease[1][2][3][4][5]. By blocking BACE1, elenbecestat decreases Aβ formation and potentially reduces amyloid plaque development in the brain. Rifampin is a well-established, broad-spectrum antibiotic that inhibits bacterial RNA polymerase. The combination would be expected to retain the mechanisms of both agents: BACE1 inhibition for Alzheimer's and bacterial RNA synthesis inhibition for infectious indications. No clinical trials or studies are found for the specific combination, but drug-drug interactions might be clinically relevant since rifampin is a strong inducer of cytochrome P450 enzymes, which could affect the metabolism of elenbecestat[2].

Other names

E-2609 + rifampin